Pfizer reported topline Phase 3 MagnetisMM-32 results for Elrexfio as monotherapy in relapsed/refractory multiple myeloma, showing a statistically significant PFS benefit and about 68% PFS at 18 months. OS data remain immature, with safety resembling prior profiles. Separately, FDA approved talazoparib with enzalutamide for mutated prostate cancer, offering additional near-term portfolio upside for Pfizer.
Pfizer rose about 3% to close at $29.21, reaching a 52-week high. JPMorgan boosted PFE's target to $30 while maintaining Neutral, signaling modest upside. The move comes amid mixed sector signals, with XAR down 1.1% and Thermo Fisher showing strength, contributing to a cautiously bullish sentiment for large-cap pharma.
Pfizer announced FDA approval of TUKYSA with trastuzumab and pertuzumab for maintenance in adults with unresectable HER2+ breast cancer, expanding its use to frontline metastatic disease after induction. The move could broaden TUKYSA's addressable market and lift near-term sales if clinicians adopt the regimen and payers reimburse. The success hinges on uptake, payer coverage, and competitive dynamics in the HER2 space.
Pfizer plans to cut about 330 jobs at its Sicily plant in Italy, per labour unions. The move underscores ongoing downsizing of Pfizer's international footprint and could affect local manufacturing capacity, though there is no stated impact on earnings guidance. Investors should monitor whether this signals broader cost-cutting or restructuring across its global operations.
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Valneva and Pfizer’s Lyme disease vaccine candidate. While Valneva’s shares jumped on the news, Pfizer’s stock impact remains uncertain and hinges on European approval and commercialization. The milestone de-risks the program and could unlock royalties or licensing opportunities if Europe approves the vaccine.
Pfizer posted Q2 earnings of $0.77 per share on $15.03 billion in sales, ahead of estimates for $0.69 and $14.41 billion. The results reinforce momentum in Pfizer's portfolio and could support near-term upside for PFE shares amid a broad market rally driven by tech leadership. Investors will scrutinize forward guidance and product mix updates for visibility on 2024–2025 profitability.
